11.02.2024, 1548 Zeichen

Marinomed: Marinomed Biotech AG has enrolled the first patient in a clinical study to investigate the lubricating properties of Carragelose eye drops in patients diagnosed with mild to moderate dry eye disease. While the product holds a valid certification under the Medical Device Directive (MDD), the study supports the switch to the new Medical Device Regulation (MDR). Carragelose eye drops are planned to launch in Austria in 2024. Furthermore, a business development process for partnering the product outside of Austria is in full swing. Next to the eye drops, also the launch of the allergen-blocking Carragelose nasal spray is planned for 2024. Marinomed has published clinical data demonstrating the effectiveness of Carragelose in the prophylactic treatment of allergic rhinitis symptoms in the nose on a pre-print server in October 2023. Now, the data have been published in the peer-reviewed International Journal of General Medicine. “In 2024, further major steps are planned for Carragelose: First, the market introduction of our Carragelose eye drops and allergen blocker; second, the launch of Barlo® nasal spray in Mexico; and third, the FDA-approval with Procter & Gamble for the first Carragelose product in the U.S. is expected. We have recently made serious progress towards the approval process and are confident that we will soon be offering our product in the world’s largest OTC market.”
Marinomed Biotech: weekly performance: -4.71%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (07/02/2024)

Christian Drastil: Wiener Börse Plausch

Soulsurfing Podcast S1/08: Die geheime Zutat – Was wirklich zählt in dem, was du tust (Monika Kletzmayr)

Bildnachweis

Aktien auf dem Radar:Frequentis, Kapsch TrafficCom, AT&S, Addiko Bank, RHI Magnesita, Zumtobel, Rosgix, VIG, Uniqa, Telekom Austria, voestalpine, Wienerberger, Palfinger, Polytec Group, Wolford, Oberbank AG Stamm, BKS Bank Stamm, Amag, Flughafen Wien, Österreichische Post, UnitedHealth, Fresenius Medical Care, Hannover Rück, Symrise, Siemens, Mercedes-Benz Group, BASF, Deutsche Post, Infineon, BMW, Merck KGaA.

---